{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:06:00Z","timestamp":1759017960991,"version":"3.44.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"am","delay-in-days":361,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.annder.2019.09.615","type":"journal-article","created":{"date-parts":[[2020,1,18]],"date-time":"2020-01-18T00:07:01Z","timestamp":1579306021000},"page":"198-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ulc\u00e9rations de l\u00e9sions cutan\u00e9es lymphomateuses sous brentuximab-v\u00e9dotin chez un patient atteint de syndrome de S\u00e9zary"],"prefix":"10.1016","volume":"147","author":[{"given":"F.","family":"Maitrepierre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Schissler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Cribier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Lipsker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2019.09.615_bib0055","first-page":"3759","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"Clin Oncol"},{"key":"10.1016\/j.annder.2019.09.615_bib0060","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas 201","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2019.09.615_bib0065","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2019.09.615_bib0070","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2217\/fon-2017-0263","article-title":"Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management","volume":"13","author":"Julia","year":"2017","journal-title":"Future Oncol"},{"key":"10.1016\/j.annder.2019.09.615_bib0075","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sezary syndrome with variable CD30\u00a0expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2019.09.615_bib0080","doi-asserted-by":"crossref","first-page":"30523","DOI":"10.18632\/oncotarget.8864","article-title":"CD30\u00a0on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30\u00a0ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro","volume":"7","author":"Hansen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.annder.2019.09.615_bib0085","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2\u00a0study of relapsed\/refractory DLBCL with variable CD30\u00a0expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.annder.2019.09.615_bib0090","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjd.13337","article-title":"Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30\u00a0expression","volume":"172","author":"Saintes","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2019.09.615_bib0095","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0190-9622(84)70259-3","article-title":"Two pattern of skin ulceration induced by methotrexate","volume":"11","author":"Lawrence","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.09.615_bib0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2310\/7750.2011.10078","article-title":"Methotrexate cutaneous ulcers in a non psoriatic patient: case report and review of the literature","volume":"15","author":"Kurian","year":"2011","journal-title":"J Cutan Med Surg"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819310877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819310877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:08:32Z","timestamp":1758971312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963819310877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0151963819310877"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2019.09.615","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ulc\u00e9rations de l\u00e9sions cutan\u00e9es lymphomateuses sous brentuximab-v\u00e9dotin chez un patient atteint de syndrome de S\u00e9zary","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2019.09.615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}